Challenges and opportunities for non-antibody scaffold drugs

Rodrigo Vazquez-Lombardi; Tri Giang Phan; Carsten Zimmermann; David Lowe; Lutz Jermutus; Daniel Christ

doi:10.1016/j.drudis.2015.09.004

Challenges and opportunities for non-antibody scaffold drugs

Drug Discov Today. 2015 Oct;20(10):1271-83. doi: 10.1016/j.drudis.2015.09.004. Epub 2015 Sep 7.

Authors

Rodrigo Vazquez-Lombardi¹, Tri Giang Phan¹, Carsten Zimmermann², David Lowe³, Lutz Jermutus⁴, Daniel Christ⁵

Affiliations

¹ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia.
² University of San Diego, School of Business Administration, 5998 Alcala Park, San Diego, CA 92110, USA.
³ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK.
⁴ MedImmune Ltd., Granta Park, Cambridge CB21 6GH, UK; Trinity Hall, University of Cambridge, Trinity Lane CB2 1TJ, UK. Electronic address: jermutusl@medimmune.com.
⁵ Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia; The University of New South Wales, Faculty of Medicine, St Vincent's Clinical School, Darlinghurst, Sydney, NSW 2010, Australia. Electronic address: d.christ@garvan.org.au.

PMID: 26360055
DOI: 10.1016/j.drudis.2015.09.004

Abstract

The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real advantages over established therapeutics to succeed in a rapidly evolving drug development landscape.

Publication types

Review

MeSH terms

Animals
Drug Delivery Systems*
Drug Design*
Humans
Proteins / administration & dosage*
Proteins / pharmacology

Substances

Proteins